Celldex Therapeutics (NASDAQ:CLDX) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note released on Monday, Marketbeat.com reports. The firm issued a neutral rating and a $45.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the stock. Wells Fargo & Company raised shares of Celldex Therapeutics from a hold rating to a strong-buy rating in a research report on Thursday, September 26th. Cantor Fitzgerald reiterated an overweight rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. Stifel Nicolaus began coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They set a buy rating and a $58.00 target price for the company. HC Wainwright reaffirmed a buy rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, September 26th. Finally, Wolfe Research lowered shares of Celldex Therapeutics from an outperform rating to a peer perform rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Celldex Therapeutics has a consensus rating of Moderate Buy and an average price target of $61.14.

Celldex Therapeutics Stock Up 2.4 %

CLDX stock opened at $33.99 on Monday. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -11.75 and a beta of 1.56. The business has a fifty day simple moving average of $38.35 and a 200-day simple moving average of $38.24. Celldex Therapeutics has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. As a group, analysts expect that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Celldex Therapeutics in the 2nd quarter worth $76,000. Teachers Retirement System of The State of Kentucky raised its stake in shares of Celldex Therapeutics by 32.0% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 40,558 shares of the biopharmaceutical company’s stock worth $1,501,000 after acquiring an additional 9,829 shares during the last quarter. Novo Holdings A S bought a new stake in shares of Celldex Therapeutics during the second quarter worth $31,458,000. Algert Global LLC grew its position in shares of Celldex Therapeutics by 75.6% during the 2nd quarter. Algert Global LLC now owns 75,614 shares of the biopharmaceutical company’s stock worth $2,798,000 after buying an additional 32,564 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of Celldex Therapeutics by 47.5% during the second quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company’s stock worth $31,294,000 after purchasing an additional 272,389 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.